Protocol Ledger

NCT07284667 · Phase II · RECRUITING

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Interventional Phase II clinical trial protocol NCT07284667 sponsored by ACADIA Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-14 Enrollment: 153 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07284667
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)153 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07284667
Protocol FieldVerified Registry Value
NCT IdentifierNCT07284667
Consolidated Lead SponsorACADIA Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment153 participants (ESTIMATED)
Registered Start Date2025-11-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07284667
Hospital Research SiteLocationSite Profile
University of Alabama at BirminghamBirmingham, ALOpen Hospital Dossier ->
Clinical Neuroscience Solutions, Inc.Orlando, FLOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI